The trajectory of Sildenafil presents a complex picture for investors. While the initial release generated significant gains, the lapse of its patent opened the door to generic competitors, dramatically diminishing https://bookmarktiger.com/story21583385/sildenafil-and-big-pharma-a-risky-bet